Clinical trial
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin…
NCT00095082 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00095082 |
|---|---|
| Title | Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes |
| Official title | Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | insulin detemir, insulin glargine, insulin aspart |
| Enrollment | 447 |
| Start date | Sep 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Nov 1, 2004 |
| Last update posted | Jan 27, 2017 |
| Countries | Finland, France, Germany, Netherlands, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: